PSTX - Poseida Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

235.9M

Cash

198.6M

Avg Qtr Burn

-17.32M

Short % of Float

8.13%

Insider Ownership

27.73%

Institutional Own.

55.31%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
P-BCMA-ALLO1 (CAR-T) Details Multiple myeloma, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
P-CD19CD20-ALLO1 Details Cancer, B-cell malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
P-MUC1C-ALLO1 Details Cancer, Breast cancer, Solid tumor/s, Ovarian cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
P-PSMA-101 (CAR-T) Details Prostate cancer, Castration-resistant prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.